BACKGROUND: Perinatally HIV-infected (PHIV) children are at risk for under-vaccination and poor vaccine response at 4 years of age. Childhood vaccine coverage and immune response were compared between PHIV and HIV-exposed uninfected (HEU) children in Latin America and the Caribbean. METHODS: PHIV and HEU children were enrolled prospectively at 15 sites from 2002 to 2009. Full vaccination by age 4 years was defined as: 3 hepatitis B virus vaccine doses; 4 tetanus toxoid-containing vaccine doses; 3 doses of Haemophilus influenzae type b vaccine by age 12 months or ≥1 dose given after age 12 months; one measles-containing vaccine dose; one rubella-containing vaccine dose. Immunity was defined by serum antibody titer. Fisher exact test (for categorical measures) and t test (for continuous measures) were used for comparisons. RESULTS: Among 519 children seen at age 4 years, 191 had serum specimens available (137 PHIV, 54 HEU). Among those with specimens available, 29.3% initiated combination antiretroviral therapy (cART) <12 months of age, 30.9% initiated at ≥12 months of age, and 39.8% had not received cART by the time they were seen at 4 years of age. At 4 years of age, 59.9% were on PI-containing cART (cART/PI), and 20.4% were on no ART. PHIV children were less likely than HEU children to be fully vaccinated for tetanus (55.5% vs. 77.8%, P = 0.005) and measles and rubella (both 70.1% vs. 94.4%, P < 0.001). Among those fully vaccinated, immunity was significantly lower among PHIV than HEU for all vaccines examined: 20.9% versus 37.8% for hepatitis B virus (P = 0.04), 72.0% versus 90.5% for tetanus (P = 0.02), 51.4% versus 68.8% for H. influenzae type b (P = 0.05), 80.2% versus 100% for measles (P < 0.001) and 72.9% versus 98.0% for rubella (P < 0.001) vaccine, respectively. CONCLUSIONS: Compared with HEU, PHIV children were significantly less likely to be immune to vaccine-preventable diseases when fully vaccinated. Strategies to increase immunity against vaccine-preventable diseases among PHIV require further study.
BACKGROUND: Perinatally HIV-infected (PHIV) children are at risk for under-vaccination and poor vaccine response at 4 years of age. Childhood vaccine coverage and immune response were compared between PHIV and HIV-exposed uninfected (HEU) children in Latin America and the Caribbean. METHODS: PHIV and HEU children were enrolled prospectively at 15 sites from 2002 to 2009. Full vaccination by age 4 years was defined as: 3 hepatitis B virus vaccine doses; 4 tetanus toxoid-containing vaccine doses; 3 doses of Haemophilus influenzae type b vaccine by age 12 months or ≥1 dose given after age 12 months; one measles-containing vaccine dose; one rubella-containing vaccine dose. Immunity was defined by serum antibody titer. Fisher exact test (for categorical measures) and t test (for continuous measures) were used for comparisons. RESULTS: Among 519 children seen at age 4 years, 191 had serum specimens available (137 PHIV, 54 HEU). Among those with specimens available, 29.3% initiated combination antiretroviral therapy (cART) <12 months of age, 30.9% initiated at ≥12 months of age, and 39.8% had not received cART by the time they were seen at 4 years of age. At 4 years of age, 59.9% were on PI-containing cART (cART/PI), and 20.4% were on no ART. PHIV children were less likely than HEU children to be fully vaccinated for tetanus (55.5% vs. 77.8%, P = 0.005) and measles and rubella (both 70.1% vs. 94.4%, P < 0.001). Among those fully vaccinated, immunity was significantly lower among PHIV than HEU for all vaccines examined: 20.9% versus 37.8% for hepatitis B virus (P = 0.04), 72.0% versus 90.5% for tetanus (P = 0.02), 51.4% versus 68.8% for H. influenzae type b (P = 0.05), 80.2% versus 100% for measles (P < 0.001) and 72.9% versus 98.0% for rubella (P < 0.001) vaccine, respectively. CONCLUSIONS: Compared with HEU, PHIV children were significantly less likely to be immune to vaccine-preventable diseases when fully vaccinated. Strategies to increase immunity against vaccine-preventable diseases among PHIV require further study.
Authors: George K Siberry; Kunjal Patel; William J Bellini; Brad Karalius; Murli U Purswani; Sandra K Burchett; William A Meyer; Sun Bae Sowers; Angela Ellis; Russell B Van Dyke Journal: Clin Infect Dis Date: 2015-06-09 Impact factor: 9.079
Authors: M I de Moraes-Pinto; A C Almeida; G Kenj; T E Filgueiras; W Tobias; A M Santos; M M Carneiro-Sampaio; C K Farhat; P J Milligan; P M Johnson; C A Hart Journal: J Infect Dis Date: 1996-05 Impact factor: 5.226
Authors: Shabir A Madhi; Locadiah Kuwanda; Leena Saarinen; Clare Cutland; Rosalia Mothupi; Helena Käyhty; Keith P Klugman Journal: Vaccine Date: 2005-08-01 Impact factor: 3.641
Authors: Omphile E Simani; Alane Izu; Avy Violari; Mark F Cotton; Nadia van Niekerk; Peter V Adrian; Shabir A Madhi Journal: AIDS Date: 2014-02-20 Impact factor: 4.177
Authors: Regina C M Succi; Margot R Krauss; D Robert Harris; Daisy M Machado; Maria Isabel de Moraes-Pinto; Marisa M Mussi-Pinhata; Noris Pavia Ruz; Russell B Pierre; Lenka Kolevic; Esau Joao; Irene Foradori; Rohan Hazra; George K Siberry Journal: Pediatr Infect Dis J Date: 2013-08 Impact factor: 2.129
Authors: Eleonora A M L Mutsaerts; Marta C Nunes; Martijn N van Rijswijk; Kerstin Klipstein-Grobusch; Kennedy Otwombe; Mark F Cotton; Avy Violari; Shabir A Madhi Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: Eleonora A M L Mutsaerts; Marta C Nunes; Martijn N van Rijswijk; Kerstin Klipstein-Grobusch; Diederick E Grobbee; Shabir A Madhi Journal: EClinicalMedicine Date: 2018-07-02
Authors: Zubairu Iliyasu; Fatimah Hassan-Hanga; Sadiq Isah Ajuji; Musa M Bello; Safiyya S Abdulkadir; Nafisa S Nass; Hamisu M Salihu; Muktar H Aliyu Journal: Int J MCH AIDS Date: 2020-12-30
Authors: Louise Afran; Kondwani C Jambo; Wilfred Nedi; David J C Miles; Anmol Kiran; Dominic H Banda; Ralph Kamg'ona; Dumizulu Tembo; Annette Pachnio; Eleni Nastouli; Brigit Ferne; Henry C Mwandumba; Paul Moss; David Goldblatt; Sarah Rowland-Jones; Adam Finn; Robert S Heyderman Journal: J Infect Dis Date: 2022-09-28 Impact factor: 7.759